Azaindole-2-carboxamide derivatives
AssigneeHoffman-La Roche Inc.
InventorsMatthias Nettekoven, Jean-Marc Plancher, Hans Richter, Olivier Roche, Sven Taylor
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula (I) wherein R1 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of 113 receptors.
Claims24
Compounds of the general formula
- wherein
- R1 is selected from the group consisting of:
- lower alkyl, lower alkenyl, lower alkinyl,
- cycloalkyl, lower cycloalkylalkyl,
- lower hydroxyalkyl,
- lower alkoxyalkyl,
- lower alkylsulfanylalkyl,
- lower dialkylaminoalkyl,
- lower dialkylcarbamoylalkyl,
- phenyl unsubstituted or substituted with one or two groups independently selected from lower alkyl, lower halogenalkoxy and lower hydroxyalkyl,
- lower phenylalkyl wherein the phenyl ring may be unsubstituted or substituted with one or two groups independently selected from lower alkyl, halogen, lower alkoxy and lower hydroxyalkyl,
- lower heteroarylalkyl wherein the heteroaryl ring may be unsubstituted or substituted with one or two groups independently selected from lower alkyl, halogen, lower alkoxy and lower hydroxyalkyl, and
- lower heterocyclylalkyl wherein the heterocyclyl ring may be unsubstituted or substituted with one or two lower alkyl groups;
- R2 is selected from the group consisting of hydrogen lower alkyl, lower alkenyl, lower alkinyl,
- cycloalkyl, lower cycloalkylalkyl,
- lower hydroxyalkyl, lower alkoxyalkyl,
- lower alkylsulfanylalkyl,
- lower dialkylaminoalkyl,
- lower dialkylcarbamoylalkyl,
- phenyl unsubstituted or substituted with one or two groups independently selected from lower alkyl, lower halogenalkoxy and lower hydroxyalkyl,
- lower phenylalkyl wherein the phenyl ring may be unsubstituted or substituted with one or two groups independently selected from lower alkyl, halogen, lower alkoxy and lower hydroxyalkyl,
- lower heteroarylalkyl wherein the heteroaryl ring may be unsubstituted or substituted with one or two groups independently selected from lower alkyl, halogen, lower alkoxy and lower hydroxyalkyl, and
- lower heterocyclylalkyl wherein the heterocyclyl ring may be unsubstituted or substituted with one or two lower alkyl groups;
- or
- R1 and R2 together with the nitrogen atom to which they are attached form a 4-, 5-, 6- or 7-membered saturated or partly unsaturated heterocyclic ring optionally containing a further heteroatom selected from nitrogen, oxygen or sulfur, a sulfinyl group or a sulfonyl group,
- said saturated or partly unsaturated heterocyclic ring being unsubstituted or substituted by one, two or three groups independently selected from lower alkyl, halogen, halogenalkyl, hydroxy, lower hydroxyalkyl, lower alkoxy, oxo, phenyl, benzyl, pyridyl and carbamoyl, or
- being condensed with a phenyl ring, said phenyl ring being unsubstituted or substituted by one, two or three groups independently selected from lower alkyl, lower alkoxy and halogen;
- R3 is selected from the group consisting of hydrogen, lower alkyl, lower hydroxyalkyl,
- lower alkoxyalkyl, lower halogenalkyl, lower cycloalkylalkyl,
- lower alkanoyl, lower cyanoalkyl, lower alkylsulfonyl,
- phenylsulfonyl wherein the phenyl ring may be unsubstituted or substituted with one or two groups independently selected from lower alkyl, halogen, lower alkoxy lower halogenalkoxy and lower hydroxyalkyl;
- phenyl unsubstituted or substituted with one or two groups independently selected from lower alkyl, halogen, lower alkoxy, lower halogenalkoxy and lower hydroxyalkyl;
- lower phenylalkyl, wherein the phenyl ring may be unsubstituted or substituted with one or two groups independently selected from lower alkyl, halogen, lower alkoxy, lower halogenalkoxy and lower hydroxyalkyl;
- and
- lower alkyl or halogen;
- R4 is hydrogen or halogen;
- R5 is a group selected from
- wherein
- m is 0, 1 or 2;
- n is 0, 1 or 2;
- X is selected from CR13R13′, O and S;
- R6, R6′, R7, R7′, R8, R8′, R13 and R13′ independently from each other are selected from the group consisting of hydrogen, lower alkyl, hydoxy, halogen and dialkylamino, or
- R7 and R13 together form a double bond;
- p is 0, 1 or 2;
- R9 is selected from lower alkyl, cycloalkyl, lower cycloalkylalkyl and lower phenylalkyl;
- q is 0, 1 or 2;
- R10 is lower alkyl;
- R11 is lower alkyl;
- R12 is lower alkyl;
- and pharmaceutically acceptable salts thereof.
Compounds of formula I according to 1, wherein R1 and R2 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from the group consisting of morpholine, piperidine, 4,4-difluoropiperidine and pyrrolidine.
Dependencies are inferred from the claim text.